See more : NXT Energy Solutions Inc. (SFD.TO) Income Statement Analysis – Financial Results
Complete financial analysis of Celldex Therapeutics, Inc. (CLDX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Celldex Therapeutics, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Stratabound Minerals Corp. (SBMIF) Income Statement Analysis – Financial Results
- Silk Road Logistics Holdings Limited (0988.HK) Income Statement Analysis – Financial Results
- Westmount Minerals Corp. (WMC.CN) Income Statement Analysis – Financial Results
- Icon Energy Limited (ICN.AX) Income Statement Analysis – Financial Results
- Aurum Pacific (China) Group Limited (8148.HK) Income Statement Analysis – Financial Results
Celldex Therapeutics, Inc. (CLDX)
About Celldex Therapeutics, Inc.
Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory diseases and various forms of cancer. The company's clinical development programs CDX-0159, a Phase I monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity; CDX-1140, a human agonist monoclonal antibody targeted to CD40, a key activator of immune response, which is found on dendritic cells, macrophages, and B cells, as well as is expressed on various cancer cells; and CDX-527, a bispecific antibody, which uses the company's proprietary active anti-PD-L1 and CD27 human antibodies to couple CD27 costimulation with blockade of the PD-L1/PD-1 pathway to help prime and activate anti-tumor T cell responses through CD27 costimulation. The company has research collaboration and license agreements with University of Southampton to develop human antibodies towards CD27; Amgen Inc. with exclusive rights to CDX-301 and CD40 ligand; and Yale University. Celldex Therapeutics, Inc. was incorporated in 1983 and is headquartered in Hampton, New Jersey.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 | 1995 | 1994 | 1993 | 1992 | 1991 | 1990 | 1989 | 1988 | 1987 | 1986 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 6.88M | 2.36M | 4.65M | 7.42M | 3.57M | 9.54M | 12.74M | 6.79M | 5.48M | 3.59M | 4.11M | 11.20M | 9.27M | 46.79M | 15.18M | 7.46M | 5.10M | 4.93M | 3.09M | 6.86M | 4.63M | 6.70M | 3.35M | 763.20K | 1.48M | 2.20M | 1.20M | 1.10M | 4.00M | 7.00M | 9.00M | 6.60M | 10.20M | 10.90M | 7.80M | 4.60M | 2.20M | 100.00K |
| Cost of Revenue | 3.01M | 1.40M | 3.07M | 42.53M | 42.67M | 66.45M | 96.17M | 102.03M | 4.01M | 101.88M | 2.33M | 10.78M | 9.12M | 12.08M | 8.40M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 41.00K | 36.80K | -689.30K | -712.80K | -400.00K | -300.00K | -100.00K | 1.20M | 1.20M | 1.50M | 600.00K | 1.10M | 800.00K | 800.00K | 300.00K | -100.00K | 0.00 |
| Gross Profit | 3.88M | 957.00K | 1.58M | -35.12M | -39.10M | -56.91M | -83.43M | -95.24M | 1.47M | -98.30M | 1.78M | 427.00K | 146.00K | 34.72M | 6.78M | 7.46M | 5.10M | 4.93M | 3.09M | 6.86M | 4.63M | 6.66M | 3.31M | 1.45M | 2.20M | 2.60M | 1.50M | 1.20M | 2.80M | 5.80M | 7.50M | 6.00M | 9.10M | 10.10M | 7.00M | 4.30M | 2.30M | 100.00K |
| Gross Profit Ratio | 56.30% | 40.60% | 34.04% | -473.39% | -1,094.29% | -596.68% | -654.70% | -1,403.48% | 26.81% | -2,741.08% | 43.23% | 3.81% | 1.58% | 74.19% | 44.68% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 99.39% | 98.90% | 190.32% | 148.05% | 118.18% | 125.00% | 109.09% | 70.00% | 82.86% | 83.33% | 90.91% | 89.22% | 92.66% | 89.74% | 93.48% | 104.55% | 100.00% |
| Research & Development | 118.01M | 82.26M | 53.31M | 42.53M | 42.67M | 66.45M | 96.17M | 102.73M | 100.17M | 104.38M | 67.40M | 47.40M | 32.44M | 27.65M | 26.17M | 26.35M | 18.50M | 18.07M | 14.06M | 13.87M | 10.02M | 14.71M | 21.58M | 10.77M | 7.87M | 5.70M | 5.30M | 6.00M | 8.00M | 8.70M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 30.91M | 27.20M | 20.49M | 14.46M | 15.43M | 19.27M | 25.00M | 35.98M | 33.84M | 20.62M | 14.81M | 10.02M | 9.24M | 10.43M | 17.12M | 14.75B | 8.50B | 0.00 | 6.89B | 0.00 | 0.00 | 0.00 | 4.91M | 4.81M | 4.28M | 3.80M | 3.50M | 6.50M | 5.90M | 5.80M | 16.00M | 0.00 | 12.90M | 11.50M | 8.30M | 6.10M | 3.70M | 1.90M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -14.73B | -8.49B | 0.00 | -6.89B | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 30.91M | 27.20M | 20.49M | 14.46M | 15.43M | 19.27M | 25.00M | 35.98M | 33.84M | 20.62M | 14.81M | 10.02M | 9.24M | 10.43M | 17.12M | 14.75M | 8.50M | 8.24M | 6.89M | 5.57M | 5.35M | 5.59M | 4.91M | 4.81M | 4.28M | 3.80M | 3.50M | 6.50M | 5.90M | 5.80M | 16.00M | 10.10M | 12.90M | 11.50M | 8.30M | 6.10M | 3.70M | 1.90M |
| Other Expenses | 12.50M | 90.34M | 55.38M | 54.02M | 42.71M | 224.00K | 896.00K | 997.00K | 1.01M | 1.01M | 1.01M | 1.09M | 1.91M | 3.14M | 345.00K | 361.01K | 960.21K | 995.11K | 995.11K | 995.10K | 995.10K | 795.10K | 1.38M | 1.31M | 1.99M | 1.00M | 400.00K | 500.00K | 700.00K | 800.00K | 900.00K | 600.00K | 600.00K | 500.00K | 300.00K | 200.00K | 200.00K | 100.00K |
| Operating Expenses | 161.43M | 109.45M | 73.80M | 56.99M | 58.10M | 85.94M | 122.07M | 139.70M | 135.02M | 126.02M | 83.22M | 58.50M | 43.60M | 41.17M | 43.63M | 41.46M | 27.96M | 27.30M | 21.95M | 20.44M | 16.37M | 21.10M | 27.87M | 16.89M | 14.14M | 10.50M | 9.20M | 13.00M | 14.60M | 15.30M | 16.90M | 10.70M | 13.50M | 12.00M | 8.60M | 6.30M | 3.90M | 2.00M |
| Cost & Expenses | 161.43M | 109.45M | 73.80M | 56.99M | 58.10M | 85.94M | 122.07M | 139.70M | 135.02M | 126.02M | 85.55M | 69.28M | 52.71M | 53.25M | 52.03M | 41.46M | 27.96M | 27.30M | 21.95M | 20.44M | 16.37M | 21.14M | 27.91M | 16.20M | 13.43M | 10.10M | 8.90M | 12.90M | 15.80M | 16.50M | 18.40M | 11.30M | 14.60M | 12.80M | 9.40M | 6.60M | 3.80M | 2.00M |
| Interest Income | 13.11M | 0.00 | 505.00K | 2.41M | 4.15M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 530.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 151.09M | 15.97M | 0.00 | 0.00 | 0.00 | 927.00K | 1.58M | 1.80M | 1.34M | 452.00K | 156.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 3.01M | 1.40M | 3.07M | 2.00M | 4.86M | 3.80M | 5.31M | 4.09M | 1.01M | 1.01M | 2.95M | 1.09M | 1.91M | 3.14M | 3.53M | 2.54M | 2.69M | 2.10M | 2.13M | 1.72M | 1.53M | 1.62M | 2.26M | 1.31M | 1.99M | 1.00M | 400.00K | 500.00K | 700.00K | 800.00K | 900.00K | 600.00K | 600.00K | 500.00K | 300.00K | 200.00K | 200.00K | 100.00K |
| EBITDA | -139.03M | -104.20M | -66.08M | -45.64M | -49.67M | -72.60M | -104.02M | -124.44M | -125.53M | -116.53M | -77.68M | -54.41M | -38.84M | 4.67M | -33.07M | -44.96M | -19.07M | -18.16M | -16.50M | -11.82M | -10.21M | -12.81M | -22.30M | -14.13M | -9.96M | -6.95M | -7.31M | -11.30M | -11.10M | -8.70M | -8.50M | -4.10M | -5.90M | -3.80M | -1.40M | -1.30M | -1.80M | -1.40M |
| EBITDA Ratio | -2,019.96% | -4,321.89% | -1,452.55% | -514.92% | -1,628.10% | -6.66% | -753.60% | -2,008.62% | -2,388.18% | -3,385.86% | -1,909.44% | -508.72% | -453.12% | -7.08% | -219.49% | -240.92% | -416.70% | -453.96% | -566.77% | -178.53% | -225.49% | -200.04% | -720.66% | -995.26% | -713.91% | 1,677.27% | -150.00% | -1,118.18% | -367.50% | -94.29% | -107.78% | -74.24% | -46.08% | -20.18% | -25.64% | -56.52% | -104.55% | -1,900.00% |
| Operating Income | -154.54M | -115.23M | -71.24M | -63.35M | -55.03M | -156.44M | -121.53M | -132.92M | -129.54M | -122.43M | -81.44M | -58.08M | -43.40M | -6.46M | -36.85M | -48.76M | -22.85M | -22.37M | -18.87M | -13.58M | -11.73M | -14.43M | -24.56M | -15.44M | -11.94M | -7.90M | -7.70M | -11.80M | -11.80M | -9.50M | -9.40M | -4.70M | -4.40M | -1.90M | -1.60M | -2.00M | -1.60M | -1.90M |
| Operating Income Ratio | -2,245.27% | -4,889.01% | -1,531.78% | -854.06% | -1,540.19% | -1,640.13% | -953.68% | -1,958.68% | -2,363.89% | -3,414.11% | -1,981.08% | -518.45% | -468.42% | -13.79% | -242.75% | -653.96% | -447.88% | -453.60% | -610.85% | -198.03% | -253.28% | -215.25% | -734.07% | -2,023.17% | -805.14% | -359.09% | -641.67% | -1,072.73% | -295.00% | -135.71% | -104.44% | -71.21% | -43.14% | -17.43% | -20.51% | -43.48% | -72.73% | -1,900.00% |
| Total Other Income/Expenses | 13.11M | 2.91M | 505.00K | 2.41M | 4.15M | 4.49M | 4.21M | 4.39M | 2.34M | 4.35M | -108.00K | -1.05M | -1.35M | 3.92M | -4.20M | 1.26M | -6.25M | 2.11M | 768.45K | 378.60K | 239.80K | 602.70K | 1.81M | -6.53M | 635.20K | 49.60K | -5.50M | 1.00M | 3.60M | -2.10M | 1.20M | 800.00K | 3.00M | 3.30M | 1.00M | 800.00K | 1.30M | 100.00K |
| Income Before Tax | -141.43M | -112.33M | -70.74M | -60.95M | -50.88M | -151.95M | -117.31M | -128.53M | -127.20M | -118.08M | -81.55M | -59.12M | -44.80M | -2.53M | -37.05M | -62.26M | -21.76M | -20.25M | -18.10M | -13.20M | -11.49M | -13.83M | -22.75M | -21.98M | -11.31M | -7.90M | -13.20M | -10.80M | -8.20M | -11.60M | -8.20M | -3.90M | -3.50M | -1.10M | -900.00K | -1.20M | -700.00K | -1.80M |
| Income Before Tax Ratio | -2,054.76% | -4,765.59% | -1,520.92% | -821.61% | -1,423.96% | -1,593.09% | -920.61% | -1,894.05% | -2,321.11% | -3,292.81% | -1,983.70% | -527.79% | -483.53% | -5.41% | -244.10% | -835.04% | -426.40% | -410.74% | -585.96% | -192.51% | -248.10% | -206.26% | -680.03% | -2,879.32% | -762.33% | -359.09% | -1,100.00% | -981.82% | -205.00% | -165.71% | -91.11% | -59.09% | -34.31% | -10.09% | -11.54% | -26.09% | -31.82% | -1,800.00% |
| Income Tax Expense | 0.00 | 10.46M | -227.00K | -1.17M | -506.00K | -765.00K | -24.28M | -8.77M | -2.34M | -4.35M | -819.00K | -530.00K | -446.00K | -5.31M | -529.00K | 27.00M | -120.00K | 120.00K | -1.54M | -757.20K | 695.70K | -1.21M | -3.62M | 13.07M | -1.27M | 87.70M | 10.90M | -2.00M | -7.10M | 4.20M | -2.80M | -1.90M | -1.90M | -1.70M | -1.20M | -1.60M | -1.70M | -300.00K |
| Net Income | -141.43M | -122.78M | -70.51M | -59.78M | -50.37M | -151.18M | -93.03M | -128.53M | -127.20M | -118.08M | -81.55M | -59.12M | -44.80M | -2.53M | -36.53M | -47.50M | -21.64M | -20.37M | -18.10M | -13.20M | -12.67M | -13.83M | -22.75M | -21.98M | -11.31M | -51.80M | -13.10M | -10.80M | -8.30M | -11.60M | -7.80M | -3.60M | -3.40M | -1.00M | -1.10M | -1.20M | -800.00K | -1.70M |
| Net Income Ratio | -2,054.76% | -5,209.29% | -1,516.04% | -805.88% | -1,409.80% | -1,585.07% | -730.06% | -1,894.05% | -2,321.11% | -3,292.81% | -1,983.70% | -527.79% | -483.53% | -5.41% | -240.61% | -637.12% | -424.05% | -413.17% | -585.96% | -192.51% | -273.47% | -206.26% | -680.03% | -2,879.32% | -762.33% | -2,354.55% | -1,091.67% | -981.82% | -207.50% | -165.71% | -86.67% | -54.55% | -33.33% | -9.17% | -14.10% | -26.09% | -36.36% | -1,700.00% |
| EPS | -2.92 | -2.62 | -1.64 | -2.02 | -3.47 | -14.48 | -10.86 | -18.99 | -19.66 | -19.81 | -15.33 | -15.37 | -17.01 | -1.19 | -27.64 | -50.12 | -468.75 | -49.41 | -43.93 | -32.57 | -36.48 | -41.17 | -70.63 | -75.43 | -46.18 | -281.04 | -89.06 | -89.61 | -85.46 | -122.55 | -82.48 | -48.26 | -57.95 | -18.89 | -23.80 | -26.22 | -17.49 | -37.21 |
| EPS Diluted | -2.92 | -2.62 | -1.64 | -2.02 | -3.47 | -14.48 | -10.86 | -18.99 | -19.66 | -19.81 | -15.33 | -15.37 | -17.01 | -1.19 | -27.64 | -50.12 | -468.75 | -49.41 | -43.93 | -32.57 | -36.48 | -41.17 | -70.63 | -75.43 | -46.18 | -281.04 | -89.06 | -89.61 | -85.46 | -122.55 | -82.48 | -48.26 | -57.95 | -18.89 | -23.80 | -26.22 | -17.49 | -37.21 |
| Weighted Avg Shares Out | 48.45M | 46.89M | 42.87M | 29.64M | 14.51M | 10.44M | 8.57M | 6.77M | 6.47M | 5.96M | 5.32M | 3.85M | 2.63M | 2.12M | 1.32M | 947.80K | 46.16K | 412.31K | 411.91K | 405.36K | 347.29K | 335.90K | 322.12K | 291.32K | 244.87K | 184.32K | 147.10K | 120.52K | 97.12K | 94.66K | 94.57K | 74.59K | 58.67K | 52.93K | 46.22K | 45.77K | 45.75K | 45.69K |
| Weighted Avg Shares Out (Dil) | 48.45M | 46.89M | 42.87M | 29.64M | 14.51M | 10.44M | 8.57M | 6.77M | 6.47M | 5.96M | 5.32M | 3.85M | 2.63M | 2.12M | 1.32M | 947.80K | 46.16K | 412.31K | 411.91K | 405.36K | 347.29K | 335.90K | 322.12K | 291.32K | 244.87K | 184.32K | 147.10K | 120.52K | 97.12K | 94.66K | 94.57K | 74.59K | 58.67K | 52.93K | 46.22K | 45.77K | 45.75K | 45.69K |
Celldex (CLDX) Down on Interim Data From Phase Ib Study in CSU
Celldex (CLDX) posts interim data from the phase Ib study evaluating barzolvolimab in patients with moderate to severe chronic spontaneous urticaria. Shares down.
Celldex (CLDX) Initiates Phase II Chronic Skin Disorder Study
Celldex (CLDX) initiates dosing in a mid-stage study designed to evaluate its antibody candidate, barzolvolimab, for treating patients with chronic spontaneous urticaria.
Celldex to Present at the 2022 Jefferies Global Healthcare Conference
HAMPTON, N.J., June 06, 2022 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced that senior management will participate in a fireside chat at the 2022 Jefferies Global Healthcare Conference in New York City on Wednesday, June 8, 2022 at...
7 Micro-Cap Stocks to Buy and Hold for the Next 10 Years
Finding micro-cap stocks to buy requires a bit of everything, including patience. Today's plan is to pick from the top of the IWC ETF.
Celldex Therapeutics (CLDX) Reports Q1 Loss, Misses Revenue Estimates
Celldex (CLDX) delivered earnings and revenue surprises of -6.52% and 76.80%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Celldex Therapeutics, Inc. (CLDX) CEO Anthony Marucci on Q4 2021 Results - Earnings Call Transcript
Celldex Therapeutics, Inc. (CLDX) CEO Anthony Marucci on Q4 2021 Results - Earnings Call Transcript
Celldex to Host Fourth Quarter and Full Year 2021 Financial Results and Corporate Highlights Conference Call
HAMPTON, N.J., Feb. 22, 2022 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced it will host a conference call and webcast on Monday, February 28, 2022 at 4:30 p.m. ET to discuss its fourth quarter and full year 2021...
Celldex: Pipeline Of Drug Candidates Is Worth A Look
CDX-0159 had good early-stage trial results for hives. CDX-1140 for cancer has some early encouraging data. CDX-527 bispecific cancer therapy is in a Phase 1 trial.
Is the Options Market Predicting a Spike in Celldex (CLDX) Stock?
Investors need to pay close attention to Celldex (CLDX) stock based on the movements in the options market lately.
Celldex to Participate in Upcoming Investor Conferences
HAMPTON, N.J., Nov. 11, 2021 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced that management will participate in fireside chats at the following virtual investor conferences in November:
Source: https://incomestatements.info
Category: Stock Reports